Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase NA 7Phase 1/2 5Phase 3 3Phase 2/3 3Phase 1 1

Status

Unknown 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Non-squamous Non-small Cell Lung Cancer 1Neoplasms 1Nasopharyngeal Carcinoma 1Liver Neoplasms 1Hodgkin Disease 1Hepatoblastoma 1Breast Neoplasms 1Advanced Solid Tumor 1Adenocarcinoma 1

Interventions

Sorafenib 8Oxaliplatin 7Bevacizumab 6sintilimab 5lenvatinib 5apatinib 5Fluorouracil 5Capecitabine 5atezolizumab 4Leucovorin 4Folfox protocol 4camrelizumab 3Drug Therapy 3tremelimumab 2durvalumab 2Thalidomide 2Radiosurgery 2Nivolumab 2Neoadjuvant Therapy 2Injections 2Hepatectomy 2Gemcitabine 2Ethiodized Oil 2regorafenib 1pirarubicin 1pembrolizumab 1menatetrenone 1liposomal doxorubicin 1lanreotide 1halofantrine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Carcinoma, Hepatocellular × camrelizumab × Clear all
NCT07309419 2025-12-30

Cocktail-001

Shanghai Zhongshan Hospital

Phase 2/3 Not yet recruiting
222 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT04521153 2025-05-11

Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma

Shanghai Zhongshan Hospital

Phase 2/3 Active not recruiting
294 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05062837 2024-01-23

Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC

Guangxi Medical University

Phase 2/3 Unknown
62 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡